A previous study using the CellSearch® assay to isolate CTCs showed that primary tumors and CTCs displayed a concordant HER2 status in 59% of breast cancer cases, and this value in metastases and CTCs was 67%25. Here, ERBB2 is linked to breast carcinoma.